Oh my. We were just getting over Alcon jettisoning the entire Kala sales force after acquiring Inveltys and Eysuvis, and now this: Allergan just let go of a massive number of eye care sales reps.
The numbers I have been hearing are staggering. Allergan has downsized its sales force, reportedly cutting 220 reps and 16 managers. These are numbers reminiscent of what happened when the Restasis patent originally expired and when Novartis acquired Xiidra from Takeda.
What are we to make of this?
There are people out there saying stuff (Read more...)